[
  {
    "ts": null,
    "headline": "Better Buy in 2026: UnitedHealth Group or Eli Lilly?",
    "summary": "These industry titans have gone in opposite directions this year; is that likely to change?",
    "url": "https://finnhub.io/api/news?id=079ee757591f8af0cf80dcf4cdc2878389a101b25365e1157b025f5d80f98cd5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766101140,
      "headline": "Better Buy in 2026: UnitedHealth Group or Eli Lilly?",
      "id": 137831373,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "These industry titans have gone in opposite directions this year; is that likely to change?",
      "url": "https://finnhub.io/api/news?id=079ee757591f8af0cf80dcf4cdc2878389a101b25365e1157b025f5d80f98cd5"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Gains Support From Daiwa and Goldman Sachs in Back-to-Back Calls",
    "summary": "Eli Lilly and Company (NYSE:LLY) is included among the 12 Best Long Term US Stocks to Buy Now. On December 16, Daiwa analyst Narumi Nakagiri upgraded Eli Lilly and Company (NYSE:LLY) to Buy from Neutral and set a $1,230 price target on the stock. That move followed a similar call from Goldman Sachs earlier. On December […]",
    "url": "https://finnhub.io/api/news?id=87115b62eda05dbe9941b49a6fd8bfa54afc5e523b3e51ff18d224aa1b0654ea",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766098250,
      "headline": "Eli Lilly (LLY) Gains Support From Daiwa and Goldman Sachs in Back-to-Back Calls",
      "id": 137831374,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is included among the 12 Best Long Term US Stocks to Buy Now. On December 16, Daiwa analyst Narumi Nakagiri upgraded Eli Lilly and Company (NYSE:LLY) to Buy from Neutral and set a $1,230 price target on the stock. That move followed a similar call from Goldman Sachs earlier. On December […]",
      "url": "https://finnhub.io/api/news?id=87115b62eda05dbe9941b49a6fd8bfa54afc5e523b3e51ff18d224aa1b0654ea"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know",
    "summary": "The latest trading day saw Eli Lilly (LLY) settling at $1, representing a +1.45% change from its previous close.",
    "url": "https://finnhub.io/api/news?id=4b6fe16120fe2bb6475d5db5e25092ba473ff4cf13264b1bfed8d3108506ddb4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766097906,
      "headline": "Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know",
      "id": 137831375,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The latest trading day saw Eli Lilly (LLY) settling at $1, representing a +1.45% change from its previous close.",
      "url": "https://finnhub.io/api/news?id=4b6fe16120fe2bb6475d5db5e25092ba473ff4cf13264b1bfed8d3108506ddb4"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly, IBD Stock Of The Day, Proves The Merit Of Its Weight-Loss Pill",
    "summary": "Eli Lilly proved the worth of its obesity pill Thursday. A study showed patients who switched to orforglipron mostly kept the weight off.",
    "url": "https://finnhub.io/api/news?id=b60316198eb74f72763750731349cbc8c052c87924c2a7de9708f5fc033c10c7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766092494,
      "headline": "Eli Lilly, IBD Stock Of The Day, Proves The Merit Of Its Weight-Loss Pill",
      "id": 137825222,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly proved the worth of its obesity pill Thursday. A study showed patients who switched to orforglipron mostly kept the weight off.",
      "url": "https://finnhub.io/api/news?id=b60316198eb74f72763750731349cbc8c052c87924c2a7de9708f5fc033c10c7"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Rise Late Afternoon",
    "summary": "Health care stocks rose late Thursday afternoon, with the NYSE Health Care Index and the State Stree",
    "url": "https://finnhub.io/api/news?id=19db29601a9f8b507d0b71b9ee7bfb22202f87089e0c225f094e9dd0e3a5f75f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766091346,
      "headline": "Sector Update: Health Care Stocks Rise Late Afternoon",
      "id": 137825223,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Health care stocks rose late Thursday afternoon, with the NYSE Health Care Index and the State Stree",
      "url": "https://finnhub.io/api/news?id=19db29601a9f8b507d0b71b9ee7bfb22202f87089e0c225f094e9dd0e3a5f75f"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Obesity Pill Maintains Weight Loss After Wegovy, Zepbound",
    "summary": "FDA filing advances orforglipron as a needle-free GLP-1 alternative.",
    "url": "https://finnhub.io/api/news?id=c3504f205837efb4ebec4fb1e586d122496d3ea71ede83e7ece057522a105d8d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766084111,
      "headline": "Eli Lilly Obesity Pill Maintains Weight Loss After Wegovy, Zepbound",
      "id": 137825224,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "FDA filing advances orforglipron as a needle-free GLP-1 alternative.",
      "url": "https://finnhub.io/api/news?id=c3504f205837efb4ebec4fb1e586d122496d3ea71ede83e7ece057522a105d8d"
    }
  },
  {
    "ts": null,
    "headline": "Viking Therapeutics, Inc. (VKTX): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Viking Therapeutics, Inc. on Alpha Talon Investment Research’s Substack by AT Investment Research. In this article, we will summarize the bulls’ thesis on VKTX. Viking Therapeutics, Inc.’s share was trading at $36.15 as of December 15th. Viking Therapeutics is a clinical-stage biotechnology company focused on metabolic and endocrine disorders, with its […]",
    "url": "https://finnhub.io/api/news?id=4bcba9bb31c069741fc537db429eb78f0da563132e6a5f6f768159d9b70d7cff",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766081601,
      "headline": "Viking Therapeutics, Inc. (VKTX): A Bull Case Theory",
      "id": 137825225,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on Viking Therapeutics, Inc. on Alpha Talon Investment Research’s Substack by AT Investment Research. In this article, we will summarize the bulls’ thesis on VKTX. Viking Therapeutics, Inc.’s share was trading at $36.15 as of December 15th. Viking Therapeutics is a clinical-stage biotechnology company focused on metabolic and endocrine disorders, with its […]",
      "url": "https://finnhub.io/api/news?id=4bcba9bb31c069741fc537db429eb78f0da563132e6a5f6f768159d9b70d7cff"
    }
  },
  {
    "ts": null,
    "headline": "Lilly says obesity pill can replace shot after weight loss",
    "summary": "Although the injectable forms of the popular GLP-1 drugs are more effective, the pills under development are both easier to take and will be cheaper",
    "url": "https://finnhub.io/api/news?id=888f67f33f56ec210bbc31d36dacd32dcea080207b00c74253cb960ad00f6fcf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766081387,
      "headline": "Lilly says obesity pill can replace shot after weight loss",
      "id": 137825226,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Although the injectable forms of the popular GLP-1 drugs are more effective, the pills under development are both easier to take and will be cheaper",
      "url": "https://finnhub.io/api/news?id=888f67f33f56ec210bbc31d36dacd32dcea080207b00c74253cb960ad00f6fcf"
    }
  },
  {
    "ts": null,
    "headline": "Better Buy in 2026: Pfizer or Eli Lilly?",
    "summary": "These two stocks have been going in opposite directions over the past few years.",
    "url": "https://finnhub.io/api/news?id=acaa472cde15f355f390181bb13a4c55de7d3b3f39d520541f285e2872a0c3f9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766077500,
      "headline": "Better Buy in 2026: Pfizer or Eli Lilly?",
      "id": 137825227,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "These two stocks have been going in opposite directions over the past few years.",
      "url": "https://finnhub.io/api/news?id=acaa472cde15f355f390181bb13a4c55de7d3b3f39d520541f285e2872a0c3f9"
    }
  },
  {
    "ts": null,
    "headline": "Rise of Direct-to-Patient GLP-1 Sales Shakes Up Care Models, HCPs Split on Pharma’s Expanding Role",
    "summary": "NEW YORK, December 18, 2025--The 43rd Barometer from Sermo, a fast, frictionless HCP social engagement platform and leader in healthcare insights, shows that pharma-led direct-to-patient (DTP) GLP-1 prescribing programs are transforming treatment access pathways. Yet findings from 953 surveyed GLP-1 prescribers reveal sharp divisions over how involved pharma should be in clinical evaluation and prescribing.",
    "url": "https://finnhub.io/api/news?id=c8c8e3e6b7110bb38f85a2394abb2c5dcfda5efab1eacbf25c992eb137694104",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766077200,
      "headline": "Rise of Direct-to-Patient GLP-1 Sales Shakes Up Care Models, HCPs Split on Pharma’s Expanding Role",
      "id": 137825228,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "NEW YORK, December 18, 2025--The 43rd Barometer from Sermo, a fast, frictionless HCP social engagement platform and leader in healthcare insights, shows that pharma-led direct-to-patient (DTP) GLP-1 prescribing programs are transforming treatment access pathways. Yet findings from 953 surveyed GLP-1 prescribers reveal sharp divisions over how involved pharma should be in clinical evaluation and prescribing.",
      "url": "https://finnhub.io/api/news?id=c8c8e3e6b7110bb38f85a2394abb2c5dcfda5efab1eacbf25c992eb137694104"
    }
  },
  {
    "ts": null,
    "headline": "Lose Weight on Zepbound, Keep It Off With Eli Lilly’s New Pill? Data Say That Works.",
    "summary": "Patients on the highly effective obesity treatments from  Novo Nordisk  and  Eli Lilly  face a dilemma after they lose weight on the drugs: Do you stay on the shots forever, or stop and risk gaining the weight back?  Now, it looks like Eli Lilly has a solution.  One idea, long discussed by Wall Street analysts, has been that Lilly and its peers could lock in long-term users with a pill for patients to switch to after shedding pounds on a shot like Lilly’s Zepbound or Novo Nordisk’s Wegovy.",
    "url": "https://finnhub.io/api/news?id=c788a2edb3e697a70c264ded957979c678f56e434805bda59a41a2d77225487e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766076840,
      "headline": "Lose Weight on Zepbound, Keep It Off With Eli Lilly’s New Pill? Data Say That Works.",
      "id": 137825229,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Patients on the highly effective obesity treatments from  Novo Nordisk  and  Eli Lilly  face a dilemma after they lose weight on the drugs: Do you stay on the shots forever, or stop and risk gaining the weight back?  Now, it looks like Eli Lilly has a solution.  One idea, long discussed by Wall Street analysts, has been that Lilly and its peers could lock in long-term users with a pill for patients to switch to after shedding pounds on a shot like Lilly’s Zepbound or Novo Nordisk’s Wegovy.",
      "url": "https://finnhub.io/api/news?id=c788a2edb3e697a70c264ded957979c678f56e434805bda59a41a2d77225487e"
    }
  },
  {
    "ts": null,
    "headline": "Why Eli Lilly (LLY) Stock Is Trading Up Today",
    "summary": "Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 2.2% in the morning session after the company released positive data from its Phase 3 \"ATTAIN-MAINTAIN\" trial, which evaluated the efficacy of its daily oral pill, orforglipron.",
    "url": "https://finnhub.io/api/news?id=24337f4ac53b96c51e8a28e0543ba585e6016391be7a5166a2b9bb2c174c5a4c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766076649,
      "headline": "Why Eli Lilly (LLY) Stock Is Trading Up Today",
      "id": 137825230,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 2.2% in the morning session after the company released positive data from its Phase 3 \"ATTAIN-MAINTAIN\" trial, which evaluated the efficacy of its daily oral pill, orforglipron.",
      "url": "https://finnhub.io/api/news?id=24337f4ac53b96c51e8a28e0543ba585e6016391be7a5166a2b9bb2c174c5a4c"
    }
  },
  {
    "ts": null,
    "headline": "3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment",
    "summary": "J&J, ImmunityBio and Foghorn Therapeutics stand out as oncology players amid rapid innovation in cancer care with advancing pipelines, approvals and partnerships.",
    "url": "https://finnhub.io/api/news?id=5726ca2ccdc787ed320a3850e679a9b9333a7f4ca24f8d2b6ffb615ba7be8661",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766072400,
      "headline": "3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment",
      "id": 137825231,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "J&J, ImmunityBio and Foghorn Therapeutics stand out as oncology players amid rapid innovation in cancer care with advancing pipelines, approvals and partnerships.",
      "url": "https://finnhub.io/api/news?id=5726ca2ccdc787ed320a3850e679a9b9333a7f4ca24f8d2b6ffb615ba7be8661"
    }
  },
  {
    "ts": null,
    "headline": "3 Momentum Stocks That Could Continue Their Strong Run in 2026",
    "summary": "AI and healthcare momentum remain strong heading into 2026. NVDA, AVGO and LLY stand out as high-growth leaders with earnings power still driving their rallies.",
    "url": "https://finnhub.io/api/news?id=cbe3cae2fc26e58718ac5ffdbf3c3b30c68c43d7f12407caa2e9f7e31e6ec46d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766071740,
      "headline": "3 Momentum Stocks That Could Continue Their Strong Run in 2026",
      "id": 137825232,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "AI and healthcare momentum remain strong heading into 2026. NVDA, AVGO and LLY stand out as high-growth leaders with earnings power still driving their rallies.",
      "url": "https://finnhub.io/api/news?id=cbe3cae2fc26e58718ac5ffdbf3c3b30c68c43d7f12407caa2e9f7e31e6ec46d"
    }
  },
  {
    "ts": null,
    "headline": "Obesity pill race heats up",
    "summary": "CNBC's Annika Kim Constantino reports on Eli Lilly after the company said its closely watched obesity pill helped patients maintain the majority of their weight loss after they switched directly from taking the company’s injection Zepbound and Novo Nordisk’s rival shot Wegovy in a late-stage trial.",
    "url": "https://finnhub.io/api/news?id=66fb8b45d66df4e0b9d82da1c8aad592c543b1c2d76fa0f18061e6374b710edc",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766071216,
      "headline": "Obesity pill race heats up",
      "id": 137833118,
      "image": "https://image.cnbcfm.com/api/v1/image/108243824-17660885611766088558-43051588031-1080pnbcnews.jpg?v=1766088560&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "CNBC's Annika Kim Constantino reports on Eli Lilly after the company said its closely watched obesity pill helped patients maintain the majority of their weight loss after they switched directly from taking the company’s injection Zepbound and Novo Nordisk’s rival shot Wegovy in a late-stage trial.",
      "url": "https://finnhub.io/api/news?id=66fb8b45d66df4e0b9d82da1c8aad592c543b1c2d76fa0f18061e6374b710edc"
    }
  },
  {
    "ts": null,
    "headline": "Can Higher-Dose Wegovy Help Novo Nordisk Regain Obesity Market Share?",
    "summary": "NVO seeks approval for a 7.2 mg Wegovy dose after study data showed stronger weight loss that can challenge Zepbound's U.S. momentum.",
    "url": "https://finnhub.io/api/news?id=1396e3512c9113cc41d2aa8aa0b73e6c0d373bd654a41a06a1c55b7a706961f4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766069580,
      "headline": "Can Higher-Dose Wegovy Help Novo Nordisk Regain Obesity Market Share?",
      "id": 137825233,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "NVO seeks approval for a 7.2 mg Wegovy dose after study data showed stronger weight loss that can challenge Zepbound's U.S. momentum.",
      "url": "https://finnhub.io/api/news?id=1396e3512c9113cc41d2aa8aa0b73e6c0d373bd654a41a06a1c55b7a706961f4"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's Weight-Loss Pill Succeeds In A First-Of-Its-Kind Study",
    "summary": "Eli Lilly proved the worth of its obesity pill Thursday. A study showed patients who switched to orforglipron mostly kept the weight off.",
    "url": "https://finnhub.io/api/news?id=6478fbb9e6fdc570c76921ffa563c14196a2ed9a2e13fd28e784e10c30fcf81e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766069374,
      "headline": "Eli Lilly's Weight-Loss Pill Succeeds In A First-Of-Its-Kind Study",
      "id": 137821569,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly proved the worth of its obesity pill Thursday. A study showed patients who switched to orforglipron mostly kept the weight off.",
      "url": "https://finnhub.io/api/news?id=6478fbb9e6fdc570c76921ffa563c14196a2ed9a2e13fd28e784e10c30fcf81e"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Lunch: Trump Media Goes Nuclear",
    "summary": "Trump Mediaâs $6B merger with fusion company TAE. Inflation drops â with caveats. OpenAI valued at $750B.",
    "url": "https://finnhub.io/api/news?id=9936328d4bf6c1468f7ab1a959e36e650d749b3ff87b81e8fba08fe5c004fadf",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766065471,
      "headline": "Wall Street Lunch: Trump Media Goes Nuclear",
      "id": 137823828,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2160790660/image_2160790660.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Trump Mediaâs $6B merger with fusion company TAE. Inflation drops â with caveats. OpenAI valued at $750B.",
      "url": "https://finnhub.io/api/news?id=9936328d4bf6c1468f7ab1a959e36e650d749b3ff87b81e8fba08fe5c004fadf"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Scores Another Major Win: Time to Buy?",
    "summary": "The company is running circles around its competition.",
    "url": "https://finnhub.io/api/news?id=c059d88dd4d27aa57cec461c14bfd954f992d69b461e8d01ee1a1c837fb604e1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766059980,
      "headline": "Eli Lilly Scores Another Major Win: Time to Buy?",
      "id": 137821570,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The company is running circles around its competition.",
      "url": "https://finnhub.io/api/news?id=c059d88dd4d27aa57cec461c14bfd954f992d69b461e8d01ee1a1c837fb604e1"
    }
  },
  {
    "ts": null,
    "headline": "Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the ATTAIN-MAINTAIN trial. The Phase 3 study evaluated orforglipron, an investigational, once-daily oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist, for weight maintenance over 52 weeks after initial treatment for 72 weeks with the highest tolerated doses of Wegovy (semaglutide) or Zepbound (tirzepatide), in participants from SURMOUNT-5 who were offered the opportunity to be re-randomized to rece",
    "url": "https://finnhub.io/api/news?id=51f839a654a7e2bb8749ffe4f4852c57e215e3d324c10ff9dad49d15367231c5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766058300,
      "headline": "Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial",
      "id": 137821571,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the ATTAIN-MAINTAIN trial. The Phase 3 study evaluated orforglipron, an investigational, once-daily oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist, for weight maintenance over 52 weeks after initial treatment for 72 weeks with the highest tolerated doses of Wegovy (semaglutide) or Zepbound (tirzepatide), in participants from SURMOUNT-5 who were offered the opportunity to be re-randomized to rece",
      "url": "https://finnhub.io/api/news?id=51f839a654a7e2bb8749ffe4f4852c57e215e3d324c10ff9dad49d15367231c5"
    }
  },
  {
    "ts": null,
    "headline": "Market Chatter: Eli Lilly and Company to Reduce Prices of its Diabetes, Weight-Loss Drugs in Canada by 20% or More",
    "summary": "Eli Lilly and Company (LLY) will reduce the prices of its diabetes and weight-loss drugs Mounjaro an",
    "url": "https://finnhub.io/api/news?id=8cf0542c43eb8e5efe165e25c00507cffc1853a619dcf935e8b7cc90246c05f4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766056625,
      "headline": "Market Chatter: Eli Lilly and Company to Reduce Prices of its Diabetes, Weight-Loss Drugs in Canada by 20% or More",
      "id": 137821572,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (LLY) will reduce the prices of its diabetes and weight-loss drugs Mounjaro an",
      "url": "https://finnhub.io/api/news?id=8cf0542c43eb8e5efe165e25c00507cffc1853a619dcf935e8b7cc90246c05f4"
    }
  },
  {
    "ts": null,
    "headline": "Better Pharmaceutical Buy: Eli Lilly vs. Novo Nordisk",
    "summary": "These two healthcare stocks have strong growth prospects, but they've been going in opposite directions.",
    "url": "https://finnhub.io/api/news?id=2de20878f46bb15c3a15d75220fc1c9a4d8ee03c41f110edc6b7834db69a400f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766049000,
      "headline": "Better Pharmaceutical Buy: Eli Lilly vs. Novo Nordisk",
      "id": 137821573,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "These two healthcare stocks have strong growth prospects, but they've been going in opposite directions.",
      "url": "https://finnhub.io/api/news?id=2de20878f46bb15c3a15d75220fc1c9a4d8ee03c41f110edc6b7834db69a400f"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound",
    "summary": "Eli Lilly also said it has filed for Food and Drug Administration approval of the daily GLP-1 pill, called orforglipron, for obesity.",
    "url": "https://finnhub.io/api/news?id=4f569e8d63c874d76a57d7bea9675df62bea5d99d1af219bfd26bfc93eaa7814",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766040329,
      "headline": "Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound ",
      "id": 137822987,
      "image": "https://image.cnbcfm.com/api/v1/image/108086195-1736866540584-gettyimages-2184000208-SINGAPORE_ELI_LILLY.jpeg?v=1761820864&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "Eli Lilly also said it has filed for Food and Drug Administration approval of the daily GLP-1 pill, called orforglipron, for obesity. ",
      "url": "https://finnhub.io/api/news?id=4f569e8d63c874d76a57d7bea9675df62bea5d99d1af219bfd26bfc93eaa7814"
    }
  }
]